WESTMINSTER, CO.  November 19, 2012 — Surefire Medical Inc., a developer of innovative high-efficiency infusion systems for the interventional radiology and interventional oncology markets, today announced the appointment of Gene McGrevin to its Board of Directors.

“Gene McGrevin is an excellent medical device strategist with a very strong background in sales, marketing and in running public companies.  As Surefire Medical transitions to full-scale commercialization in the U.S., Europe and Asia, Gene’s addition to the Surefire Board is both timely and a great gain for the company,” said Surefire Medical Board chairman Norman Weldon.

With 25 years of senior management positions in the medical industry at companies including Johnson & Johnson and Kimberly-Clark Corporation, Mr. McGrevin also was instrumental in the expansion and sale of several medical startups.  They include PetNet Pharmaceuticals (sold to Siemens), Microtek Medical Holdings (sold to EcoLabs), and Medivance (sold to C.R. Bard).

“In my judgment Surefire Medical has the three key ingredients for success in the marketplace,” McGrevin said.   “The company has innovative technology that physicians are quickly adopting due to its proven clinical impact on patient care.  It has strong IP.  And with higher embolization, Surefire Medical’s infusion devices are cost-effective as well as clinically relevant.”

Mr. McGrevin also serves on the Boards of the Yerkes Primate Center, Real Time Medical Data and HydroDynamics.

“We are delighted that Gene has joined the Board of Directors of Surefire Medical,” said Jim Chomas, Chief Executive Officer.  “Gene’s extensive experience in strategic market development brings additional valuable perspective to our Board.  I look forward to his contributions as we advance Surefire Medical’s growth strategy.”

Mr. McGrevin holds an MBA from the University of Pennsylvania’s Wharton School.  He earned a BA in economics at the University of Pittsburgh.

Achievement

Clinical Data Shows Surefire Technology Achieved 79% Objective Response versus 37% Using a Standard Microcatheter in Treating Primary Liver Cancer. Study presented at SIR 2017 Annual Scientific Meeting.